Pirtobrutinib for Malignancies, Hematologic

Phase-Based Progress Estimates
M D Anderson Cancer Center, Houston, TX
Malignancies, Hematologic+5 More
Pirtobrutinib - Drug
All Sexes
What conditions do you have?

Study Summary

To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

Eligible Conditions

  • Malignancies, Hematologic
  • Mantle Cell Lymphoma (MCL)
  • Non-Hodgkin's Lymphoma (NHL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Malignancies, Hematologic

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion an average of 1 year.

Year 1
ORR (overall response rate)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Malignancies, Hematologic

Trial Design

1 Treatment Group

Pirtobrutinib (LOXO-305) and Venetoclax (combination)
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Pirtobrutinib · No Placebo Group · Phase 2

Pirtobrutinib (LOXO-305) and Venetoclax (combination)Experimental Group · 2 Interventions: Pirtobrutinib, Venetoclax · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion an average of 1 year.
Closest Location: M D Anderson Cancer Center · Houston, TX
Photo of Houston 1Photo of Houston 2Photo of Houston 3
2003First Recorded Clinical Trial
1 TrialsResearching Malignancies, Hematologic
465 CompletedClinical Trials

Who is running the clinical trial?

Loxo OncologyUNKNOWN
M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,795,182 Total Patients Enrolled
10 Trials studying Malignancies, Hematologic
443 Patients Enrolled for Malignancies, Hematologic
Preetesh Jain, MD, DM, PhDPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a performance status of 2 or less.
You have relapsed or refractory MCL.
You are willing and capable of giving informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.